Company overview
Cellectricon provides customized in vitro neurobiology research services to accelerate early drug discovery for pharmaceutical clients. Their offerings include target discovery, lead discovery, phenotypic screening, and neurotoxicity testing using complex models like primary neuronal cultures, iPSC-derived neurons, and tri-cultures of neurons, astrocytes, and microglia. Based in Sweden, they focus on areas such as peripheral neuropathies, neuroinflammation, neurodegeneration, and neuroplasticity, leveraging expertise in cell biology and advanced technologies.
Cellectricon is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include cellectricon, neurobiology services, drug discovery, in vitro screening, neuroscience assays.
Products and technologies associated with Cellectricon include Assay — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://cellectricon.com/
- Markets served
- United States & Americas
- Keywords
- cellectricon, neurobiology services, drug discovery, in vitro screening, neuroscience assays
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What are Cellectricon's core capabilities in pharma drug discovery?
- Cellectricon specializes in target discovery, lead discovery, phenotypic and target-based assay development, screening, lead optimization, and neurotoxicity testing using physiologically relevant in vitro neurobiology models.
- What regulatory standards or quality practices does Cellectricon follow?
- Cellectricon adheres to pharmaceutical industry standards with robust best practices, ensuring high-quality primary cell cultures and assays for high-capacity applications, though specific regulatory certifications are not detailed.
- Where is Cellectricon located and what geographies do they serve?
- Cellectricon is based in Mölndal, Sweden, and serves global pharmaceutical and biotech clients, including partnerships with companies like Delix Therapeutics.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
- Verge Rebrands AI Drug Discovery After Trial Setback
- Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen
- BBSW AI Solution Event: Daily Roundup
- BBSW AI Solution Event: Biotech Innovation in US
Explore lab tools and QA/QC resources for R&D teams.
